Posts Tagged ‘immunosuppression protocols’

June 21, 2013

Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

New immunosuppressant agents face a high standard: theymust show comparable or superior results as current treatments with less side effects. Sotrastaurin is an oral medication that blocks protein kinase C to prevent T cell activation. In this randomized controlled trial, sotrastaurin combined with tacrolimus, steroids and basiliximab showed similar rates of acute rejection and graft […]

No Comments Posted in Renal Transplantation
April 1, 2013

Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Post-transplant, mycophenolic acid (MPA) dose is frequently reduced because of side effects or toxicity. However, overall MPA levels are higher in patients on tacrolimus as opposed to cyclosporine. In this prospective study of patients who were also on tacrolimus, MPA dose reduction or discontinuation was associated with a higher risk of subsequent acute rejection. The […]

No Comments Posted in Pancreas Transplantation, Renal Transplantation
April 14, 2012

Conversion from Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3-Year Results from the Randomized ZEUS Study

This paper prevents further results from a randomized controlled trial of mandatory conversion from cyclosporine to everolimus. There remains a higher acute rejection rate in the everolimus-treated patients. However, renal function remained better in the everolimus arm. As in many such trials, a significant number of patients treated with everolimus had to change to other […]

No Comments Posted in Renal Transplantation